| A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth (NCT05181839) | Kyowa Kirin Pharmaceutical Development Ltd | 2021-11-24 |
| Burden of Disease and Functional Impairment in XLH (NCT04946409) | Wuerzburg University Hospital | 2020-10-01 |
| Foot Disorders in X-linked Hypophosphatemia (NCT06067932) | Orthopedic Hospital Vienna Speising | 2020-07-01 |
| Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls (NCT04273490) | University of Aarhus | 2020-02-18 |
| Examining the Effect of Burosumab on Muscle Function (NCT04146935) | Yale University | 2019-11-13 |
| Dental Implants in Patients With X-linked Hypophosphatemia (NCT03879915) | Assistance Publique - Hôpitaux de Paris | 2019-09-27 |
| Calcitriol Monotherapy for X-Linked Hypophosphatemia (NCT03748966) | Massachusetts General Hospital | 2019-03-28 |
| Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH (NCT03920072) | Kyowa Kirin Pharmaceutical Development Ltd | 2019-03-07 |
| X-linked Hypophosphatemia and FGF21 (NCT03596554) | Hospices Civils de Lyon | 2019-01-11 |
| FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) (NCT03489993) | Wake Forest University Health Sciences | 2018-12-06 |
| X-linked Hypophosphatemia Disease Monitoring Program (NCT03651505) | Ultragenyx Pharmaceutical Inc | 2018-07-16 |
| Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners (NCT03745521) | Kyowa Kirin Co., Ltd. | 2018-05-01 |
| Burosumab in Children and Adolescents With X-linked Hypophosphatemia (NCT04419363) | Bicetre Hospital | 2018-03-18 |
| Registry for Patients With X-Linked Hypophosphatemia (NCT03193476) | Kyowa Kirin Pharmaceutical Development Ltd | 2017-09-12 |
| Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia (NCT03820518) | Peking Union Medical College Hospital | 2017-01-01 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH (NCT02915705) | Kyowa Kirin, Inc. | 2016-09-08 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) (NCT02750618) | Kyowa Kirin, Inc. | 2016-05-05 |
| Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) (NCT02537431) | Kyowa Kirin, Inc. | 2015-12-23 |
| Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) (NCT02526160) | Kyowa Kirin, Inc. | 2015-10-22 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) (NCT02312687) | Kyowa Kirin, Inc. | 2015-01-30 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) (NCT02163577) | Kyowa Kirin, Inc. | 2014-07-02 |
| An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia (NCT01571596) | Kyowa Kirin Co., Ltd. | 2012-02-01 |
| A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia (NCT01340482) | Kyowa Kirin Co., Ltd. | 2011-04-01 |
| A Study of KRN23 in X-linked Hypophosphatemia (NCT00830674) | Kyowa Kirin Co., Ltd. | 2008-12-01 |
| Expanded Access to Burosumab (NCT03775187) | Kyowa Kirin Co., Ltd. | |